Account

Background Heartbeat

Medical Cannabis for Fibromyalgia: What a South African Prescriber Weighs

A person easing neck and shoulder pain outdoors, the widespread chronic pain behind questions about medical cannabis for fibromyalgia

Direct answer: Medical cannabis for fibromyalgia is not an approved treatment in South Africa. No cannabis medicine is registered here for fibromyalgia, so any prescription runs through a SAHPRA Section 21 authorisation for an unregistered product, decided case by case. The published evidence is genuinely limited: the largest systematic review found low-quality evidence for short-term pain reduction across nine studies. A registered doctor weighs that against your history and your other medicines.

Last updated:

Key takeaways

  • Strand and colleagues, in Biomedicines in 2023, reviewed 9 studies covering 564 patients, 4 randomised controlled trials and 5 observational studies. Their verdict was low-quality evidence supporting short-term pain reduction.
  • Their own concluding sentence is deliberately modest: although current evidence is limited, medical cannabis appears to be a safe alternative for treating fibromyalgia. Limited is doing real work in that sentence.
  • Results are inconsistent between trials. Van de Donk and colleagues in 2019 found no significant effect on spontaneous pain against placebo, while 90 percent of participants on one product reached a 30 percent pain reduction against 55 percent on placebo.
  • The AHRQ living systematic review on cannabis for chronic pain reached its 2025 update with 29 randomised controlled trials and 15 observational studies, and still described the strength of that evidence as mostly low.
  • Reported side effects across the fibromyalgia studies were drowsiness, dizziness, dry mouth, nausea and vomiting, and gastrointestinal symptoms. No severe adverse effects were documented in the studies reviewed.
  • Nothing here is a dosing instruction. In South Africa the dose, the product and the decision to prescribe at all belong to a registered doctor.

What does the evidence on medical cannabis for fibromyalgia actually show?

Less than the internet suggests, and more than nothing. The most useful single document is the systematic review by Strand, Maloney, Kraus and colleagues published in Biomedicines in 2023, which pooled 9 studies covering 564 patients: 4 randomised controlled trials and 5 observational studies.

Their assessment was that the evidence supporting short-term pain reduction is low quality. That is a technical grading, not an insult. It means the studies were small, varied in design, used different products and different outcome measures, and that further research could easily change the estimate.

The individual results show exactly that spread. Skrabek and colleagues in 2008 compared nabilone with placebo and reported a fall in visual analogue scale pain of 2.04 cm and an improvement of 12.07 points on the Fibromyalgia Impact Questionnaire, both at p less than 0.02. Ware and colleagues in 2010 compared nabilone with amitriptyline and found a difference of 3.2 on the Insomnia Severity Index, with a 95 percent confidence interval of 1.2 to 5.3.

Then Van de Donk and colleagues in 2019 found no significant effect on spontaneous pain against placebo, while at the same time 90 percent of participants on one preparation achieved a 30 percent pain reduction compared with 55 percent on placebo. Sagy and colleagues in 2019, an observational study rather than a trial, reported median pain falling from 9.0 to 5.0 with 81.1 percent classed as responders. Observational results run higher than trial results, which is a pattern worth noticing rather than a finding to rely on.

A person pointing to a painful spot on their back, typical of the widespread pain reported in fibromyalgia

Why is the evidence so hard to pin down?

Because fibromyalgia is difficult to measure and cannabis is difficult to standardise, and the two problems multiply.

Fibromyalgia has no confirmatory laboratory test. Outcomes are patient-reported: pain scales, impact questionnaires, sleep indices. Those measures are legitimate but they are noisy, and placebo response in chronic pain trials is substantial, which is precisely why the placebo arm in the 2019 trial still reached 55 percent.

On the other side, cannabis is not one intervention. The studies above used nabilone, a synthetic cannabinoid taken as a capsule, and inhaled preparations with different tetrahydrocannabinol and cannabidiol contents. The AHRQ living review recorded a 2024 self-titration trial by van Dam and colleagues in 81 people, testing purified inhaled cannabis at 6.3 percent THC and 8 percent CBD against 5 mg oxycodone tablets or both together. A capsule of a synthetic cannabinoid and an inhaled whole-plant preparation are not the same treatment, and pooling them flattens real differences.

The honest summary is the one the AHRQ reviewers gave when they reached 29 randomised controlled trials and 15 observational studies for chronic pain overall in 2025: the strength of the evidence was mostly low. For the broader picture beyond this one condition, see our page on medical cannabis for chronic pain in South Africa.

Before you start

In South Africa, cannabis containing tetrahydrocannabinol is prescription-only through a registered doctor, in most cases via a SAHPRA Section 21 authorisation. This page is general information for adults aged 18 and over and is not medical advice, and nothing here says that cannabis treats or cures fibromyalgia. Do not stop or change an existing fibromyalgia medicine on your own. Speak to a doctor or pharmacist before starting, stopping or changing any treatment, and discuss dosing with them.

How does a South African patient lawfully reach it?

Through a doctor, and through Section 21. Tetrahydrocannabinol sits in Schedule 6 of the Medicines and Related Substances Act 101 of 1965, most recently amended by Government Notice R5181 in Government Gazette 51171 on 6 September 2024. Schedule 6 means prescription only, dispensed by a pharmacy.

The second layer is registration. A medicine registered by SAHPRA for a named indication can be prescribed in the ordinary way. Cannabis products used for fibromyalgia here are not in that position, so the prescriber applies under section 21 of the Act for authorisation to use an unregistered medicine in a named patient. Our step-by-step guide to SAHPRA Section 21 explains who the applicant actually is, which surprises most people: it is the prescriber, not you.

That has a practical consequence. You cannot shop your way to a Section 21 authorisation, and no platform can grant one. The decision sits with a doctor who has assessed you and who is prepared to make the application and take responsibility for it.

It also means a refusal is a normal clinical outcome rather than an administrative failure. A prescriber who declines has usually weighed the low-quality evidence base against something specific in your history.

What will a doctor weigh before prescribing?

The first thing is whether the standard options have genuinely been tried. Fibromyalgia has established pharmacological and non-pharmacological management, and a prescriber considering an unregistered product will usually want to know what has already been attempted and what happened.

The second is interaction and comorbidity. Many people with fibromyalgia are taking antidepressants, anticonvulsants, sleep medication or opioids. Cannabinoids can add to sedation, and the 2024 trial described above was designed around exactly this question of combining an inhaled preparation with an opioid. Your full medicine list matters more here than any statistic on this page.

The third is the side effect profile against the size of the expected benefit. The reviewed fibromyalgia studies reported drowsiness, dizziness, dry mouth, nausea and vomiting and gastrointestinal symptoms, with no severe adverse effects documented. Those are tolerable for some people and disqualifying for others, particularly anybody who drives for work or lives alone. Our page on the side effects of weed goes through what is actually recorded and how often.

The fourth is what success would look like and when you would stop. A prescriber working carefully sets a review point in advance, because an unregistered medicine with low-quality evidence behind it should not be continued indefinitely on hope.

A doctor seated at a clinic desk with a stethoscope, where a prescribing decision is actually made

What medical cannabis for fibromyalgia cannot promise

It cannot promise a cure, because nothing in the literature claims one. The strongest honest statement available is the one the Biomedicines reviewers wrote: although current evidence is limited, medical cannabis appears to be a safe alternative for treating fibromyalgia. Read that as a statement about tolerability in the studies reviewed, not as a claim of efficacy.

It cannot promise a response, because trial results disagree with one another and a large proportion of the apparent benefit in chronic pain studies also appears in placebo arms.

It cannot promise access, because a Section 21 authorisation is a clinical decision made by a prescriber about one named patient, and it can be declined.

And it cannot promise a dose. Anyone giving you a milligram figure for fibromyalgia off a webpage is guessing, because the studies used different products by different routes and none of that transfers to you without a clinician. Our companion page on cannabis and fibromyalgia covers the evidence base in more general terms if you want the wider view.

How Professor Green fits into the process

Professor Green is a South African medical cannabis access platform and a marketing affiliate of the Dr Green network, which holds the medical cannabis licences in South Africa. Professor Green does not itself sell, handle or ship cannabis. Products are sold and fulfilled by the licensed operator.

Professor Green does not diagnose, does not assess you, does not prescribe and does not apply for a Section 21 authorisation. Those are acts performed by a registered medical practitioner. A pharmacy dispenses against the prescription, and a licensed operator supplies and delivers.

Registering creates an account and starts the doctor-led process. It is not a guarantee of eligibility, of a prescription, of stock or of supply, and nothing on this page claims that any product treats fibromyalgia.

Researching medical cannabis for fibromyalgia and want the question put to a doctor rather than to a search engine? Create your Professor Green account to begin the doctor-led route. A registered doctor decides whether to assess, prescribe or decline. Registration does not guarantee eligibility, a prescription or supply.

The bottom line

Medical cannabis for fibromyalgia occupies an uncomfortable middle ground, and the discomfort is the accurate position. Nine studies in 564 patients, graded low quality. One trial finding no effect on spontaneous pain while a responder analysis in the same trial looks striking. An observational study reporting median pain halving. A 2025 chronic pain review at 29 trials still calling the evidence mostly low.

If you take one thing from that, take this: it is a reasonable question to raise with a doctor and an unreasonable thing to decide for yourself. Bring your full medicine list, bring an honest account of what you have already tried, and expect a conversation about a trial period with a review date rather than a prescription on the spot. In South Africa that conversation is where the decision legally lives, and it is also where it belongs.

Frequently asked questions

Is cannabis an approved treatment for fibromyalgia in South Africa?
No. No cannabis medicine is registered here for fibromyalgia, so a prescription runs through a SAHPRA Section 21 authorisation for an unregistered medicine, applied for by the prescriber for one named patient.

How strong is the research?
Weak by design standards. Strand and colleagues in Biomedicines in 2023 reviewed 9 studies covering 564 patients and graded the evidence for short-term pain reduction as low quality. The AHRQ chronic pain living review reached 29 trials in 2025 and still called the evidence mostly low.

Did any trial show no benefit?
Yes. Van de Donk and colleagues in 2019 found no significant effect on spontaneous pain compared with placebo, although 90 percent of participants on one preparation reached a 30 percent pain reduction against 55 percent on placebo.

What side effects were reported?
Across the reviewed fibromyalgia studies the common effects were drowsiness, dizziness, dry mouth, nausea and vomiting, and gastrointestinal symptoms. No severe adverse effects were documented in those studies.

Can I get a dose recommendation from this page?
No. The studies used different products by different routes, including a synthetic cannabinoid capsule and inhaled preparations, and none of that transfers to an individual. Dosing is a clinical decision for a registered doctor or pharmacist.

Should I stop my current fibromyalgia medicine?
Not without medical advice. Several medicines commonly used in fibromyalgia interact with sedation, and stopping some of them abruptly causes problems of its own. Raise any change with the prescriber who started it.

Who applies for the Section 21 authorisation?
The prescriber, not the patient. It is an application to use an unregistered medicine in a named patient, so the doctor who assessed you makes it and carries responsibility for the decision.

Can a doctor say no?
Yes, and a refusal is an ordinary clinical outcome. Given the low quality of the evidence base, a prescriber who declines has usually weighed something specific in your history against a small and uncertain expected benefit.

Sources and references

Research figures above are the study authors’ own and were read on 20 September 2026. Scheduling in South Africa changes by Gazette notice and the evidence base is a living one that is updated, so verify anything time-sensitive before relying on it. General information for adults aged 18 and over. This is not medical advice and is not a claim that any product treats fibromyalgia.

Want this question put to a doctor?

If you have read the evidence on medical cannabis for fibromyalgia and want a registered doctor to weigh it against your own history, the next step is to create a Professor Green account and begin the doctor-led route. The doctor assesses, decides whether to prescribe and applies for any Section 21 authorisation. A pharmacy dispenses and a licensed operator supplies. Registration does not guarantee eligibility, a prescription or supply.

Create Your Professor Green Account
Share the Post:

Related Posts

Professorgreen.co.za is ran by Green Tec LLC is an authorised marketing affiliate for the Dr Green network who holds the Medical Cannabis licences in South Africa. We do not sell, handle, or ship cannabis. All cannabis products are sold and fulfilled by licensed operator DR Green.

Our Social